Gilead Sciences (GILD) Total Current Liabilities (2009 - 2026)
Gilead Sciences' (GILD) quarterly Total Current Liabilities came in at $9.5 billion in Q1 2026, down 23.23% YoY from $12.3 billion in Q1 2025, and down 19.78% on a QoQ basis from $11.8 billion in Q4 2025.
Gilead Sciences (GILD) Total Current Liabilities (2009 - 2026) Analysis & Trends
Gilead Sciences (GILD) has 18 years of Total Current Liabilities data on file, last reported at $9.5 billion in Q1 2026.
- Quarterly Total Current Liabilities fell 23.23% year-over-year to $9.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $9.5 billion (down 23.23% YoY) and the FY2025 annual result came in at $11.8 billion, down 1.59% from the prior year.
- Total Current Liabilities fell to $9.5 billion in Q1 2026, from $11.8 billion in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $14.0 billion in Q2 2023 to a low of $8.6 billion in Q1 2022.
- A 5-year average of $11.3 billion and a median of $11.3 billion in 2023 frame the typical range for Total Current Liabilities.
- Annual changes were most pronounced in 2023 — Total Current Liabilities jumped 51.45% — and 2026, when it fell 23.23%.
- Tracing GILD's Total Current Liabilities over 5 years: stood at $11.2 billion in 2022, then advanced by 0.38% to $11.3 billion in 2023, then advanced by 6.42% to $12.0 billion in 2024, then fell by 1.59% to $11.8 billion in 2025, then decreased by 19.78% to $9.5 billion in 2026.
- The last three Total Current Liabilities figures came in at $9.5 billion (Q1 2026), $11.8 billion (Q4 2025), and $12.3 billion (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 651.77 Bn | 631.01 Bn | 17.26 Bn | 54.90 Bn |
| 2 | AbbVie | 470.29 Bn | 463.72 Bn | 12.70 Bn | 41.64 Bn |
| 3 | Merck | 374.97 Bn | 367.83 Bn | 12.21 Bn | 27.73 Bn |
| 4 | Novartis Ag | 302.80 Bn | 295.11 Bn | 11.24 Bn | 31.75 Bn |
| 5 | Astrazeneca | 257.17 Bn | 252.27 Bn | 12.86 Bn | 31.55 Bn |
| 6 | Amgen | 236.88 Bn | 222.89 Bn | 7.24 Bn | 25.50 Bn |
| 7 | Gilead Sciences | 182.68 Bn | 179.50 Bn | 6.22 Bn | 11.02 Bn |
| 8 | Pfizer | 159.74 Bn | 148.04 Bn | 10.94 Bn | 32.65 Bn |
| 9 | Gsk | 106.06 Bn | 101.89 Bn | 8.24 Bn | -28.89 Bn |
| 10 | Sanofi | 55.17 Bn | 47.79 Bn | 10.79 Bn | 37.11 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.02 Bn |
| Mar 31, 2026 | 9.48 Bn |
| Dec 31, 2025 | 11.81 Bn |
| Sep 30, 2025 | 12.30 Bn |
| Jun 30, 2025 | 11.19 Bn |
| Mar 31, 2025 | 12.34 Bn |
| Dec 31, 2024 | 12.00 Bn |
| Sep 30, 2024 | 11.73 Bn |
| Jun 30, 2024 | 10.78 Bn |
| Mar 31, 2024 | 13.02 Bn |
| Dec 31, 2023 | 11.28 Bn |
| Sep 30, 2023 | 11.95 Bn |
| Jun 30, 2023 | 13.96 Bn |
| Mar 31, 2023 | 10.53 Bn |
| Dec 31, 2022 | 11.24 Bn |
| Sep 30, 2022 | 10.42 Bn |
| Jun 30, 2022 | 9.22 Bn |
| Mar 31, 2022 | 8.56 Bn |
| Dec 31, 2021 | 11.61 Bn |
| Sep 30, 2021 | 10.25 Bn |